Health & Fitness
The Next Generation of Weight-Loss Drugs: Retatrutide, CagriSema, and What Comes After
Retatrutide cut weight 28 percent in Phase 3 trials. CagriSema pairs amylin with a GLP-1. Daily pills are already approved. Here is the honest state of the next-generation obesity drug pipeline as of October 2026.
